NCT06415292View on ClinicalTrials.gov

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

December 16, 2023

Study Completion Date

December 16, 2023

Conditions

Acne Vulgaris

Interventions

DRUG

Winlevi (clascoterone) 1% cream

Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.

Trial Locations (1)

27262

Dermatology Consulting Services, PLLC, High Point

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT06415292 - A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients | Biotech Hunter | Biotech Hunter